Allogene Therapeutics (ALLO) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Allogene Therapeutics (NASDAQ: ALLO) in the last few weeks:

• 8/15/2024 – Allogene Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
• 8/9/2024 – Allogene Therapeutics had its price target raised by analysts at Citigroup Inc. from $7.00 to $8.00. They now have a “buy” rating on the stock.
• 8/9/2024 – Allogene Therapeutics had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $14.00 price target on the stock, down previously from $17.00.
• 8/8/2024 – Allogene Therapeutics is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $11.00 price target on the stock.
• 8/8/2024 – Allogene Therapeutics had its price target lowered by analysts at Canaccord Genuity Group Inc. from $35.00 to $14.00. They now have a “buy” rating on the stock.

Allogene Therapeutics Price Performance

Allogene Therapeutics stock opened at $2.68 on Wednesday. The company has a market capitalization of $560.12 million, a PE ratio of -1.50 and a beta of 0.85. Allogene Therapeutics, Inc. has a one year low of $2.01 and a one year high of $5.78. The business has a 50 day simple moving average of $2.59 and a 200 day simple moving average of $3.29.

Insider Buying and Selling

In related news, Director Franz B. Humer sold 11,200 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total transaction of $26,208.00. Following the completion of the transaction, the director now owns 255,253 shares in the company, valued at approximately $597,292.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 24.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Allogene Therapeutics

Several institutional investors have recently bought and sold shares of the business. Primecap Management Co. CA raised its position in Allogene Therapeutics by 4.1% in the 2nd quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock valued at $13,212,000 after purchasing an additional 221,840 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Allogene Therapeutics by 76.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock valued at $18,675,000 after buying an additional 1,806,147 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at $6,349,000. Dimensional Fund Advisors LP increased its stake in shares of Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after buying an additional 507,021 shares during the period. Finally, Lynx1 Capital Management LP acquired a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at $5,192,000. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).